Meta-analysis: probiotics as adjunct to conventional therapy in rotavirus enteritis
Adding probiotics to conventional therapy significantly shortens resolution times for diarrhea, fever, and vomiting in rotavirus enteritis, with a consistent favorable direction across all primary clinical outcomes.
| Outcome | Grade | Direction | Effect | Studies |
|---|---|---|---|---|
| Time to normalized stool frequency | A | ▲ Favorable | MD 1.18 IC 0.76/1.60 | 14 |
| Antidiarrheal time | A | ▲ Favorable | MD 1.17 IC 1.02/1.32 | 14 |
| Body temperature normalization | A | ▲ Favorable | MD 0.83 IC 0.58/1.08 | 14 |
| Vomiting cessation | A | ▲ Favorable | MD 1.00 IC 0.61/1.39 | 14 |
| Total effective rate | A | ▲ Favorable | RR 0.85 IC 0.82/0.88 | 14 |
| Immunoglobulin levels (IgA and IgG) | C | ▲ Favorable | melhora significativa; dados numéricos não disponíveis no texto | — |
| Safety (adverse events) | B | — Neutral | RR 1.38 IC 0.74/2.56 p>0.05 | 14 |
Context
Rotavirus enteritis causes over 200,000 deaths annually in children under 5 and has no specific etiological treatment. The oral rotavirus vaccine achieves only 58% real-world efficacy in low-income settings per the 2024 WHO position paper. Safe and effective adjuncts to supportive therapy are needed.
What the study showed
Probiotics shortened time to normalized stool frequency by 1.18 days (MD=1.18; 95% CI: 0.76–1.60; p<0.00001), antidiarrheal time by 1.17 days (MD=1.17; 95% CI: 1.02–1.32; p<0.00001), body temperature recovery by 0.83 days (MD=0.83; 95% CI: 0.58–1.08; p<0.00001), and vomiting cessation by 1.00 day (MD=1.00; 95% CI: 0.61–1.39; p<0.00001). Total effective rate favored the probiotic group (RR=0.85; 95% CI: 0.82–0.88; p<0.00001). IgA and IgG levels improved significantly, though detailed numerical data for these outcomes were not provided in the available text. Safety was comparable between groups (RR=1.38; 95% CI: 0.74–2.56; p>0.05), with no statistically significant difference in adverse events.
How it was done
Systematic review and meta-analysis of 14 RCTs totaling 1,709 patients, retrieved from multiple databases. The available text does not specify which databases were searched, detailed inclusion criteria, probiotic strains used, doses, duration of individual interventions, or precise age range of participants. The risk-of-bias assessment tool is not identified in the available excerpt.
Effect magnitude
Mean differences for time-based outcomes range from 0.83 to 1.18 days in favor of probiotics, with confidence intervals not crossing zero; absolute clinical magnitude is modest given typical hospitalizations of 3–7 days for rotavirus enteritis. An RR of 0.85 for total effective rate indicates a 15% relative reduction in therapeutic failure risk.
Limitations
The available text does not describe the risk-of-bias tool applied (e.g., RoB 2, AMSTAR-2), precluding formal methodological quality assessment of included RCTs. Heterogeneity in strains, doses, and populations is not detailed, limiting extrapolation to specific strains. The apparent predominance of Chinese studies restricts generalizability to other populations and healthcare contexts.
In clinical practice
Combining probiotics with conventional therapy may shorten diarrhea, fever, and vomiting duration by approximately 1 day in rotavirus enteritis; the absolute benefit is modest. Clinicians should note that optimal strain, dose, and target population are not defined by this meta-analysis, and applicability outside the Chinese context requires caution.
What is still missing
Clinical trials with standardized strain identification, dose, and duration are needed to establish precise therapeutic recommendations. Studies in low-income populations outside the Asian context are absent.